Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells an… Read more
Statera Biopharma Inc (STAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2022: 0.079x
Based on the latest financial reports, Statera Biopharma Inc (STAB) has a cash flow conversion efficiency ratio of 0.079x as of September 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-801.52K) by net assets ($-10.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Statera Biopharma Inc - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Statera Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Statera Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Statera Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nam A Commercial Joint Stock Bank Ordinary Shares
VN:NAB
|
N/A |
|
Ben Thanh Rubber JSC
VN:BRC
|
N/A |
|
CARCLO (C1Y.SG)
STU:C1Y
|
N/A |
|
Rapid-Line Inc.
OTCGREY:RPDL
|
39.666x |
|
Nowigence Inc.
OTCQB:NOWG
|
N/A |
|
Doan Xa Port JSC
VN:DXP
|
N/A |
|
CHINA TELECOM -H-
MU:ZCH
|
0.102x |
|
Khairpur Sugar Mills Ltd
KAR:KPUS
|
N/A |
Annual Cash Flow Conversion Efficiency for Statera Biopharma Inc (2012–2022)
The table below shows the annual cash flow conversion efficiency of Statera Biopharma Inc from 2012 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-1.51 Million | $-28.19 Million | 18.711x | 0.00% |
| 2021-12-31 | $-1.51 Million | $-28.19 Million | 18.711x | +1245.94% |
| 2020-12-31 | $-3.66 Million | $-5.08 Million | 1.390x | +778.47% |
| 2019-12-31 | $-1.52 Million | $-240.37K | 0.158x | +112.40% |
| 2018-12-31 | $3.61 Million | $-4.61 Million | -1.277x | -43.04% |
| 2017-12-31 | $7.41 Million | $-6.61 Million | -0.892x | -127.49% |
| 2016-12-31 | $12.85 Million | $-5.04 Million | -0.392x | +51.17% |
| 2015-12-31 | $15.04 Million | $-12.08 Million | -0.803x | -105.58% |
| 2014-12-31 | $-1.00 Billion | $-14.46 Billion | 14.401x | +198.55% |
| 2013-12-31 | $1.58 Billion | $-23.10 Billion | -14.613x | -1349.70% |
| 2012-12-31 | $20.49 Billion | $-20.65 Billion | -1.008x | -- |